Christine Prager
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christine Prager has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
- Angela M. Kaindl
Department of Pediatric Neurology, Charité – Universitätsmedizin Berlin, Germany
7 shared publications - Konstantin L. Makridis
Department of Pediatric Neurology Charité – Universitätsmedizin Berlin Berlin Germany
3 shared publications - Anna Tietze
Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neuroradiology, Berlin, Germany
2 shared publications - Christian Erich Elger
Department of Epileptology, University Hospital Bonn, Bonn, Germany
2 shared publications Deniz A. Atalay
Department of Pediatric Neurology, Charité – Universitätsmedizin Berlin, Germany
2 shared publications- Fabienne Kühne
Department of Neonatology, Charité - University Medicine Berlin, Berlin, Germany
2 shared publications
Latest Publications
- 29 August 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 101 (9) , E879-E891
Natural History and Developmental Trajectories of Individuals With Disease-Causing Variants in STXBP1
Background and Objectives: Pathogenic variants in STXBP1 are among the major genetic causes of neurodevelopmental disorders. Despite the increasing number of individuals diagnosed without a history of epilepsy, little is known about the natural history and developmental trajectories in this subgroup and endpoints for future therapeutic studies are limited to seizure control. Methods: We performed a cross-sectional retrospective study using standardized questionnaires for clinicians and caregivers of individuals with STXBP1-related disorders capturing medical histories, genetic findings, and developmental outcomes. Motor and language function were assessed using Gross Motor Function Classification System scores (GMFCS) and a speech impairment score and were compared within and across clinically defined subgroups. Results: We collected data of 71 individuals with STXBP1-related disorders, including 44 previously unreported individuals. Median age at inclusion was 5.3 years (IQR = 3.5-9.3) with the oldest individual aged 43.8 years. Epilepsy was absent in 18/71 (25%) of individuals. The range of developmental outcomes was broad, including two individuals presenting with close to age-appropriate motor development. 29/61 (48%) individuals were able to walk unassisted and 24/69 (35%) were able to speak single words. Individuals without epilepsy presented with a similar onset and spectrum of phenotypic features but had lower GMFCS scores (median 3 vs. 4, p < 0.01) than individuals with epilepsy. Individuals with epileptic spasms were less likely to walk unassisted than individuals with other seizure types (6% vs. 58%, p < 0.01). Individuals with early epilepsy onset had higher speech impairment scores (p = 0.02) than individuals with later epilepsy onset. Discussion: We expand the spectrum of STXBP1-related disorders and provide clinical features and developmental trajectories in individuals with and without a history of epilepsy. Individuals with epilepsy, in particular epileptic spasms, and neonatal or early-onset, presented with less favorable motor and language functional outcomes compared to individuals without epilepsy. These findings identify children at risk for severe disease and can serve as comparator for future interventional studies in STXBP1-related disorders.
- 29 August 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 101 (9) , E879-E891
Natural History and Developmental Trajectories of Individuals With Disease-Causing Variants in STXBP1
Background and Objectives: Pathogenic variants in STXBP1 are among the major genetic causes of neurodevelopmental disorders. Despite the increasing number of individuals diagnosed without a history of epilepsy, little is known about the natural history and developmental trajectories in this subgroup and endpoints for future therapeutic studies are limited to seizure control. Methods: We performed a cross-sectional retrospective study using standardized questionnaires for clinicians and caregivers of individuals with STXBP1-related disorders capturing medical histories, genetic findings, and developmental outcomes. Motor and language function were assessed using Gross Motor Function Classification System scores (GMFCS) and a speech impairment score and were compared within and across clinically defined subgroups. Results: We collected data of 71 individuals with STXBP1-related disorders, including 44 previously unreported individuals. Median age at inclusion was 5.3 years (IQR = 3.5-9.3) with the oldest individual aged 43.8 years. Epilepsy was absent in 18/71 (25%) of individuals. The range of developmental outcomes was broad, including two individuals presenting with close to age-appropriate motor development. 29/61 (48%) individuals were able to walk unassisted and 24/69 (35%) were able to speak single words. Individuals without epilepsy presented with a similar onset and spectrum of phenotypic features but had lower GMFCS scores (median 3 vs. 4, p < 0.01) than individuals with epilepsy. Individuals with epileptic spasms were less likely to walk unassisted than individuals with other seizure types (6% vs. 58%, p < 0.01). Individuals with early epilepsy onset had higher speech impairment scores (p = 0.02) than individuals with later epilepsy onset. Discussion: We expand the spectrum of STXBP1-related disorders and provide clinical features and developmental trajectories in individuals with and without a history of epilepsy. Individuals with epilepsy, in particular epileptic spasms, and neonatal or early-onset, presented with less favorable motor and language functional outcomes compared to individuals without epilepsy. These findings identify children at risk for severe disease and can serve as comparator for future interventional studies in STXBP1-related disorders.
- Open Access
Primidone improves symptoms in TRPM3‐linked developmental and epileptic encephalopathy with spike‐and‐wave activation in sleep
Developmental and epileptic encephalopathy with continuous spike‐and‐wave activation in sleep (CSWS) or DEE‐SWAS is an age‐dependent disease, often accompanied by a decline in cognitive abilities. Early successful treatment of CSWS is associated with a better cognitive outcome. We retrospectively analyzed the clinical, electrophysiological, radiological, and genetic data of children with DEE‐SWAS associated with melastatin‐related transient receptor type 3 gene (TRPM3) missense variants. We report two unrelated children with pharmacoresistant DEE‐SWAS and developmental delay/regression and different heterozygous de novo missense variants in the TRPM3 gene (NM_001366145.2; c.3397 T > C/p.Ser1133Pro, c.2004G > A/p.Val1002Met). The variant p.Val1002Met (previously known as p.Val990Met or p.Val837Met) and p.Ser1133Pro were recently shown to result in a gain‐of‐function effect. Based on this finding, previous drug resistance, and the experimentally demonstrated inhibitory effect of primidone on TRPM3, we initiated an individualized therapy with this drug. In both children, developmental regression was stopped, psychomotor development improved, and CSWS was no longer detectable. To our knowledge, this is the first report of a treatment with primidone in TRPM3‐associated CSWS. Our results highlight the importance of early genetic diagnosis in patients with epilepsy and the possibility of precision medicine, which should be considered in the future in individuals with a TRPM3‐linked DEE‐SWAS.
Open AccessPrimidone improves symptoms in TRPM3‐linked developmental and epileptic encephalopathy with spike‐and‐wave activation in sleep
Developmental and epileptic encephalopathy with continuous spike‐and‐wave activation in sleep (CSWS) or DEE‐SWAS is an age‐dependent disease, often accompanied by a decline in cognitive abilities. Early successful treatment of CSWS is associated with a better cognitive outcome. We retrospectively analyzed the clinical, electrophysiological, radiological, and genetic data of children with DEE‐SWAS associated with melastatin‐related transient receptor type 3 gene (TRPM3) missense variants. We report two unrelated children with pharmacoresistant DEE‐SWAS and developmental delay/regression and different heterozygous de novo missense variants in the TRPM3 gene (NM_001366145.2; c.3397 T > C/p.Ser1133Pro, c.2004G > A/p.Val1002Met). The variant p.Val1002Met (previously known as p.Val990Met or p.Val837Met) and p.Ser1133Pro were recently shown to result in a gain‐of‐function effect. Based on this finding, previous drug resistance, and the experimentally demonstrated inhibitory effect of primidone on TRPM3, we initiated an individualized therapy with this drug. In both children, developmental regression was stopped, psychomotor development improved, and CSWS was no longer detectable. To our knowledge, this is the first report of a treatment with primidone in TRPM3‐associated CSWS. Our results highlight the importance of early genetic diagnosis in patients with epilepsy and the possibility of precision medicine, which should be considered in the future in individuals with a TRPM3‐linked DEE‐SWAS.
- Open Access
WWOXdevelopmental and epileptic encephalopathy: Understanding the epileptology and the mortality risk
Objective: WWOXis an autosomal recessive cause of early infantile developmental and epileptic encephalopathy (WWOX‐DEE), also known as WOREE (WWOX‐related epileptic encephalopathy). We analyzed the epileptology and imaging features ofWWOX‐DEE, and investigated genotype–phenotype correlations, particularly with regard to survival.Methods: We studied 13 patients from 12 families withWWOX‐DEE. Information regarding seizure semiology, comorbidities, facial dysmorphisms, and disease outcome were collected. Electroencephalographic (EEG) and brain magnetic resonance imaging (MRI) data were analyzed. PathogenicWWOXvariants from our cohort and the literature were coded as either null or missense, allowing individuals to be classified into one of three genotype classes: (1) null/null, (2) null/missense, (3) missense/missense. Differences in survival outcome were estimated using the Kaplan–Meier method.Results: All patients experienced multiple seizure types (median onset = 5 weeks, range = 1 day–10 months), the most frequent being focal (85%), epileptic spasms (77%), and tonic seizures (69%). Ictal EEG recordings in six of 13 patients showed tonic (n = 5), myoclonic (n = 2), epileptic spasms (n = 2), focal (n = 1), and migrating focal (n = 1) seizures. Interictal EEGs demonstrated slow background activity with multifocal discharges, predominantly over frontal or temporo‐occipital regions. Eleven of 13 patients had a movement disorder, most frequently dystonia. Brain MRIs revealed severe frontotemporal, hippocampal, and optic atrophy, thin corpus callosum, and white matter signal abnormalities. Pathogenic variants were located throughoutWWOXand comprised both missense and null changes including five copy number variants (four deletions, one duplication). Survival analyses showed that patients with two null variants are at higher mortality risk (p‐value = .0085, log‐rank test).Significance: BiallelicWWOXpathogenic variants cause an early infantile developmental and epileptic encephalopathy syndrome. The most common seizure types are focal seizures and epileptic spasms. Mortality risk is associated with mutation type; patients with biallelic nullWWOXpathogenic variants have significantly lower survival probability compared to those carrying at least one presumed hypomorphic missense pathogenic variant.
Open AccessWWOXdevelopmental and epileptic encephalopathy: Understanding the epileptology and the mortality risk
Objective: WWOXis an autosomal recessive cause of early infantile developmental and epileptic encephalopathy (WWOX‐DEE), also known as WOREE (WWOX‐related epileptic encephalopathy). We analyzed the epileptology and imaging features ofWWOX‐DEE, and investigated genotype–phenotype correlations, particularly with regard to survival.Methods: We studied 13 patients from 12 families withWWOX‐DEE. Information regarding seizure semiology, comorbidities, facial dysmorphisms, and disease outcome were collected. Electroencephalographic (EEG) and brain magnetic resonance imaging (MRI) data were analyzed. PathogenicWWOXvariants from our cohort and the literature were coded as either null or missense, allowing individuals to be classified into one of three genotype classes: (1) null/null, (2) null/missense, (3) missense/missense. Differences in survival outcome were estimated using the Kaplan–Meier method.Results: All patients experienced multiple seizure types (median onset = 5 weeks, range = 1 day–10 months), the most frequent being focal (85%), epileptic spasms (77%), and tonic seizures (69%). Ictal EEG recordings in six of 13 patients showed tonic (n = 5), myoclonic (n = 2), epileptic spasms (n = 2), focal (n = 1), and migrating focal (n = 1) seizures. Interictal EEGs demonstrated slow background activity with multifocal discharges, predominantly over frontal or temporo‐occipital regions. Eleven of 13 patients had a movement disorder, most frequently dystonia. Brain MRIs revealed severe frontotemporal, hippocampal, and optic atrophy, thin corpus callosum, and white matter signal abnormalities. Pathogenic variants were located throughoutWWOXand comprised both missense and null changes including five copy number variants (four deletions, one duplication). Survival analyses showed that patients with two null variants are at higher mortality risk (p‐value = .0085, log‐rank test).Significance: BiallelicWWOXpathogenic variants cause an early infantile developmental and epileptic encephalopathy syndrome. The most common seizure types are focal seizures and epileptic spasms. Mortality risk is associated with mutation type; patients with biallelic nullWWOXpathogenic variants have significantly lower survival probability compared to those carrying at least one presumed hypomorphic missense pathogenic variant.
- Open Access
- 6 February 2023
- Published by Wiley in Epilepsia Open
- Vol. 8 (2) , 360-370
Real‐world data on cannabidiol treatment of various epilepsy subtypes: A retrospective, multicenter study
Objective: Cannabidiol (CBD) is approved for treatment of Dravet syndrome (DS), Lennox‐Gastaut syndrome (LGS), and tuberous sclerosis complex (TSC). Several studies suggest antiseizure effects also beyond these three epilepsy syndromes.Methods: In a retrospective multicenter study, we analyzed the efficacy and tolerability of CBD in patients with epilepsy at 16 epilepsy centers.Results: The study cohort comprised 311 patients with epilepsy with a median age of 11.3 (0‐72) years (235 children and adolescents, 76 adults). Therapy with CBD was off‐label in 91.3% of cases due to age, epilepsy subtype, lack of adjunct therapy with clobazam, and/or higher dose applied. CBD titration regimens were slower than recommended, with good tolerability of higher doses particularly in children. Of all patients, 36.9% experienced a reduction in seizure frequency of >50%, independent of their epilepsy subtype or clobazam co‐medication. The median observation period was 15.8 months. About one third of all patients discontinued therapy within the observation period due to adverse effects or lack of efficacy. Adverse effects were reported frequently (46.9%).Significance: Our study highlights that CBD has an antiseizure effect comparable to other antiseizure medications with a positive safety profile independent of the epilepsy subtype. Comedication with clobazam was not associated with a better outcome. Higher doses to achieve seizure frequency reduction were safe, particularly in children. These findings call for further trials for an extended approval of CBD for other epilepsy subtypes and for children <2 years of age.
- 6 February 2023
- Published by Wiley in Epilepsia Open
- Vol. 8 (2) , 360-370
Open AccessReal‐world data on cannabidiol treatment of various epilepsy subtypes: A retrospective, multicenter study
Objective: Cannabidiol (CBD) is approved for treatment of Dravet syndrome (DS), Lennox‐Gastaut syndrome (LGS), and tuberous sclerosis complex (TSC). Several studies suggest antiseizure effects also beyond these three epilepsy syndromes.Methods: In a retrospective multicenter study, we analyzed the efficacy and tolerability of CBD in patients with epilepsy at 16 epilepsy centers.Results: The study cohort comprised 311 patients with epilepsy with a median age of 11.3 (0‐72) years (235 children and adolescents, 76 adults). Therapy with CBD was off‐label in 91.3% of cases due to age, epilepsy subtype, lack of adjunct therapy with clobazam, and/or higher dose applied. CBD titration regimens were slower than recommended, with good tolerability of higher doses particularly in children. Of all patients, 36.9% experienced a reduction in seizure frequency of >50%, independent of their epilepsy subtype or clobazam co‐medication. The median observation period was 15.8 months. About one third of all patients discontinued therapy within the observation period due to adverse effects or lack of efficacy. Adverse effects were reported frequently (46.9%).Significance: Our study highlights that CBD has an antiseizure effect comparable to other antiseizure medications with a positive safety profile independent of the epilepsy subtype. Comedication with clobazam was not associated with a better outcome. Higher doses to achieve seizure frequency reduction were safe, particularly in children. These findings call for further trials for an extended approval of CBD for other epilepsy subtypes and for children <2 years of age.
- Open Access
- 11 January 2022
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 37, 53-55
Is cannabidiol worth a trial in Rasmussen encephalitis?
- 11 January 2022
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 37, 53-55
Open AccessIs cannabidiol worth a trial in Rasmussen encephalitis?
- 28 October 2021
- Published by Georg Thieme Verlag KG in Neuropediatrics
- Vol. 52 (S 01) , FV2.04
Epilepsy Surgery in Children with Minimal Presurgical Video-EEG Monitoring
Background: Epilepsy surgery can potentially cure drug-resistant epilepsy, but careful presurgical evaluation is vital to select patients who will profit from such an intervention. Many epilepsy surgery programs offer extensive presurgical evaluation including several days of video EEG monitoring. Non-lesional epilepsy cases are rare upon epilepsy-surgery patients. We therefore set up a lesion-orientated pediatric epilepsy surgery program for patients with clearly localized lesions that involved only minimal presurgical diagnostics, particularly with max. 48 hours of non-invasive EEG monitoring that did not necessarily include ictal EEGs. Methods: We evaluated retrospectively the outcome of patients who were operated within our epilepsy surgery program with respect to seizure freedom and cognition. Results: Of 135 patients evaluated for epilepsy surgery, 36 children and adolescents underwent a resective procedure at a mean age of 8.37 ± 4.7 years (range: 0.35–18.78). The most frequent surgery was a hemispherotomy. Overall seizure freedom was 73.9% after 12 months and 77.8% at a current median observation period of 16.5 months. Seizure frequency was reduced <50% in all other patients. After surgery, IQ values increased slightly from mean 59.87 ± 26.29 to 63.46 ± 28.71. In patients who had lost IQ points after surgery, no cognitive regression occurred. These patients developed more slowly than children with an average development speed. Individually they achieved better results than preoperatively or stagnated. Conclusion: Despite the limits due to the patient selection, our findings highlight the high success rate using a lesion-orientated epilepsy surgery approach with reduced presurgical video EEG monitoring in the pediatric epilepsy population. Publication Date: 28 October 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 28 October 2021
- Published by Georg Thieme Verlag KG in Neuropediatrics
- Vol. 52 (S 01) , FV2.04
Epilepsy Surgery in Children with Minimal Presurgical Video-EEG Monitoring
Background: Epilepsy surgery can potentially cure drug-resistant epilepsy, but careful presurgical evaluation is vital to select patients who will profit from such an intervention. Many epilepsy surgery programs offer extensive presurgical evaluation including several days of video EEG monitoring. Non-lesional epilepsy cases are rare upon epilepsy-surgery patients. We therefore set up a lesion-orientated pediatric epilepsy surgery program for patients with clearly localized lesions that involved only minimal presurgical diagnostics, particularly with max. 48 hours of non-invasive EEG monitoring that did not necessarily include ictal EEGs. Methods: We evaluated retrospectively the outcome of patients who were operated within our epilepsy surgery program with respect to seizure freedom and cognition. Results: Of 135 patients evaluated for epilepsy surgery, 36 children and adolescents underwent a resective procedure at a mean age of 8.37 ± 4.7 years (range: 0.35–18.78). The most frequent surgery was a hemispherotomy. Overall seizure freedom was 73.9% after 12 months and 77.8% at a current median observation period of 16.5 months. Seizure frequency was reduced <50% in all other patients. After surgery, IQ values increased slightly from mean 59.87 ± 26.29 to 63.46 ± 28.71. In patients who had lost IQ points after surgery, no cognitive regression occurred. These patients developed more slowly than children with an average development speed. Individually they achieved better results than preoperatively or stagnated. Conclusion: Despite the limits due to the patient selection, our findings highlight the high success rate using a lesion-orientated epilepsy surgery approach with reduced presurgical video EEG monitoring in the pediatric epilepsy population. Publication Date: 28 October 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 28 October 2021
- Published by Georg Thieme Verlag KG in Neuropediatrics
- Vol. 52 (S 01) , P2.06
Behavioral Disorder following a Hemispherotomy in Association with Valproate
Background/Purpose: Epilepsy surgery is the only treatment that can potentially cure lesional epilepsy. Therefore in most cases, a hemispherotomy is performed. These surgeries are based on the predominant lesion types and high potential of plasticity in children's brains. This relation allows a compensation of the later persistent functional separation of hemispheres. Methods: We describe an acute aggravation of behavioral problems following a hemispherotomy in a patient treated with valproate which subsided once valproate was discontinued. Results: Our 9-year-old patient underwent hemispherotomy due to drug-resistant epilepsy caused by the residua of a perinatal stroke. Shortly after surgery, his pre-operative behavioral problems intensified dramatically with additional new symptoms of aggression. Assuming a correlation between valproic acid treatment and a postoperative altered neuronal network we tapered off valproic acid. Shortly after reducing the dosage, the intensity of behavioral problems decreased, and finally disappeared after discontinuation of valproic acid. Conclusion: We describe possible altered effects of anticonvulsants after hemispherotomy and subsequent changed network function to raise awareness about/of potential valproate-associated behavioral changes after hemispherotomy. Publication Date: 28 October 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 28 October 2021
- Published by Georg Thieme Verlag KG in Neuropediatrics
- Vol. 52 (S 01) , P2.06
Behavioral Disorder following a Hemispherotomy in Association with Valproate
Background/Purpose: Epilepsy surgery is the only treatment that can potentially cure lesional epilepsy. Therefore in most cases, a hemispherotomy is performed. These surgeries are based on the predominant lesion types and high potential of plasticity in children's brains. This relation allows a compensation of the later persistent functional separation of hemispheres. Methods: We describe an acute aggravation of behavioral problems following a hemispherotomy in a patient treated with valproate which subsided once valproate was discontinued. Results: Our 9-year-old patient underwent hemispherotomy due to drug-resistant epilepsy caused by the residua of a perinatal stroke. Shortly after surgery, his pre-operative behavioral problems intensified dramatically with additional new symptoms of aggression. Assuming a correlation between valproic acid treatment and a postoperative altered neuronal network we tapered off valproic acid. Shortly after reducing the dosage, the intensity of behavioral problems decreased, and finally disappeared after discontinuation of valproic acid. Conclusion: We describe possible altered effects of anticonvulsants after hemispherotomy and subsequent changed network function to raise awareness about/of potential valproate-associated behavioral changes after hemispherotomy. Publication Date: 28 October 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 28 October 2021
- Published by Georg Thieme Verlag KG in Neuropediatrics
- Vol. 52 (S 01) , P2.31
Don’t Miss Migraines in Patients with Drug-Resistant Epilepsy
Headaches can occur following epilepsy surgery, and differentiating primary (e.g., migraine) from secondary (e.g., intracranial hypertension) headaches can be a challenge. A female patient developed drug-resistant epilepsy with epilepsia partialis continua at the age of 10 years with progressive cognitive decline, prompting the diagnosis of Rasmussen's encephalitis. At 12 years of age, a right-side hemispherotomy was performed and brought forth seizure freedom. Post hemispherotomy, the girl presented repeatedly to our clinic for severe headaches, lasting up to 15 days. She reported 10 to 15 headache days per month. Secondary headache causes including intracranial hypertension were excluded. Remission was achieved through intravenous metamizole and oral ibuprofen, but headaches returned rapidly as soon as treatment was terminated. Retrospectively, the girl had experienced recurrent headaches already prior to hemispherotomy; however, her ability to communicate pain had been severely impaired at that time due to her primary disease. Her headaches met all required criteria for a migraine without aura. She was therefore given 7.5 mg/kg magnesium citrate daily as preventive treatment and instructed to use sumatriptan or metamizole as acute medication. These measures substantially improved headache frequency and attack duration. With this case report, we would like to point toward the possibility of a primary headache in patients with drug-resistant epilepsy and post epilepsy surgery as a differential diagnosis to secondary headaches such as intracranial hypertension. Introspection and ability to articulate headaches can be impaired in patients with drug-resistant epilepsy and hinder proper diagnosis and therapy. A substantial decrease of headache attack frequency can be achieved through simple measures. Publication Date: 28 October 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 28 October 2021
- Published by Georg Thieme Verlag KG in Neuropediatrics
- Vol. 52 (S 01) , P2.31
Don’t Miss Migraines in Patients with Drug-Resistant Epilepsy
Headaches can occur following epilepsy surgery, and differentiating primary (e.g., migraine) from secondary (e.g., intracranial hypertension) headaches can be a challenge. A female patient developed drug-resistant epilepsy with epilepsia partialis continua at the age of 10 years with progressive cognitive decline, prompting the diagnosis of Rasmussen's encephalitis. At 12 years of age, a right-side hemispherotomy was performed and brought forth seizure freedom. Post hemispherotomy, the girl presented repeatedly to our clinic for severe headaches, lasting up to 15 days. She reported 10 to 15 headache days per month. Secondary headache causes including intracranial hypertension were excluded. Remission was achieved through intravenous metamizole and oral ibuprofen, but headaches returned rapidly as soon as treatment was terminated. Retrospectively, the girl had experienced recurrent headaches already prior to hemispherotomy; however, her ability to communicate pain had been severely impaired at that time due to her primary disease. Her headaches met all required criteria for a migraine without aura. She was therefore given 7.5 mg/kg magnesium citrate daily as preventive treatment and instructed to use sumatriptan or metamizole as acute medication. These measures substantially improved headache frequency and attack duration. With this case report, we would like to point toward the possibility of a primary headache in patients with drug-resistant epilepsy and post epilepsy surgery as a differential diagnosis to secondary headaches such as intracranial hypertension. Introspection and ability to articulate headaches can be impaired in patients with drug-resistant epilepsy and hinder proper diagnosis and therapy. A substantial decrease of headache attack frequency can be achieved through simple measures. Publication Date: 28 October 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany